Data-driven drug development company Emyria has released new research indicating opioid use and pain decline in patients using medicinal cannabis over a consistent period, while quality of life scores improve.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Join or login

The company measured opioid use over at least six months among more than 500 of its Emerald Clinic patients suffering from chronic non-cancer pain.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...